68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorPeking Union Medical College Hospital
About this trial
Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. In this study, a novel dual-target imaging agent 68Ga-RM26-RGD was used for clinical study of tumor PET/CT imaging to further verify its clinical application value.
Eligibility criteria
Qualifiers
patients with confirmed or suspected breast/brain/prostate cancer;
68Ga-RM26-RGD and 18F-FDG(or 68Ga-RM26 or 68Ga-RGD) PET/CT within 2 week;
signed written consent.
Disqualifiers
pregnancy;
breastfeeding;
any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Trial design
Treatments tested in this trial
- 68Ga-RM26-RGD
- 18F-FDG
- 68Ga-RM26
- 68Ga-RGD
Treatment groups
90 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov